We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+16.05%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$11.4B
AUM Growth
-$622M
Cap. Flow
-$2.95B
Cap. Flow %
-25.85%
Top 10 Hldgs %
75.13%
Holding
138
New
10
Increased
24
Reduced
17
Closed
12

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$1.13B
2
ABBV icon
AbbVie
ABBV
+$938M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$82.3M
4
ATYR
aTyr Pharma
ATYR
+$51.8M
5
DYAX
DYAX CORPORATION
DYAX
+$50.5M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$2.31B
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$1.14B
3
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$38M
4
VNDA icon
Vanda Pharmaceuticals
VNDA
+$14.5M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 72.4%
2 Technology 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGMO
26
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$35.8M 0.31%
3,230,932
+1,826,388
+130% +$23.5M
IMGN
27
DELISTED
Immunogen Inc
IMGN
$33.4M 0.29%
2,320,424
+1,320,928
+132% +$14.5M
TGTX icon
28
TG Therapeutics
TGTX
$8.16B
$33.2M 0.29%
2,003,991
-46,322
-2% -$733K
PGNX
29
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$32.5M 0.28%
4,350,808
– –
CPRX
30
DELISTED
Catalyst Pharmaceutical
CPRX
$30.3M 0.27%
7,335,692
-229,770
-3% -$916K
GILD icon
31
Gilead Sciences
GILD
$167B
$29.3M 0.26%
249,995
– –
KYTH
32
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$29.2M 0.26%
387,741
+33,476
+9% +$1.79M
NBIX icon
33
Neurocrine Biosciences
NBIX
$18.3B
$25.9M 0.23%
542,236
– –
ACGN
34
DELISTED
Aceragen Inc
ACGN
$25.9M 0.23%
51,308
+40
+0.1% +$18.4K
BLUE
35
DELISTED
bluebird bio
BLUE
$25.4M 0.22%
11,665
+349
+3% +$711K
DSCI
36
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$24.8M 0.22%
3,457,841
– –
ACOR
37
DELISTED
Acorda Therapeutics
ACOR
$24.6M 0.22%
6,158
– –
NVAX icon
38
Novavax
NVAX
$1.19B
$21.7M 0.19%
97,284
– –
FOMX
39
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$21M 0.18%
2,046,967
+225,000
+12% +$2.49M
XNCR icon
40
Xencor
XNCR
$1.44B
$19.2M 0.17%
872,072
– –
LKFT
41
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$19M 0.17%
+369,276
New +$19.6M
CLVS
42
DELISTED
Clovis Oncology, Inc.
CLVS
$17.8M 0.16%
202,630
– –
OMER icon
43
Omeros
OMER
$834M
$17.4M 0.15%
964,621
+327,175
+51% +$7.06M
ZGNX
44
DELISTED
Zogenix, Inc.
ZGNX
$16.8M 0.15%
1,253,571
+966,263
+336% +$11.8M
IOVA icon
45
Iovance Biotherapeutics
IOVA
$2.02B
$16.7M 0.15%
1,817,429
+492,429
+37% +$5.5M
PRQR icon
46
ProQR Therapeutics
PRQR
$244M
$16.5M 0.14%
988,299
+588,299
+147% +$11.1M
RPRX
47
DELISTED
Repros Therapeutics Inc.
RPRX
$14M 0.12%
1,955,944
-44,056
-2% -$343K
ACHN
48
DELISTED
Achillion Pharmaceuticals
ACHN
$13.5M 0.12%
1,523,739
+1,309,502
+611% +$12.4M
RARE icon
49
Ultragenyx Pharmaceutical
RARE
$2.51B
$12.7M 0.11%
123,894
-25,000
-17% -$1.94M
MTEM
50
DELISTED
Molecular Templates, Inc.
MTEM
$11.8M 0.1%
17,730
– –
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2015 Portfolio in Review

As of Q2 2015, Baker Bros. Advisors held 138 positions worth $11.4B, down 5.2% from $12B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Baker Bros. Advisors withdrew a net $2.95B in Q2 2015, closing 12 positions and reducing 17 holdings. Its most notable exit was PHARMACYCLICS INC, an estimated $2.31B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 40% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in Alexion Pharmaceuticals worth $1.18B.

  • Baker Bros. Advisors's largest Q2 2015 buy was Alexion Pharmaceuticals: 6,542,599 shares worth $1.18B.
  • Baker Bros. Advisors added most to Seagen Inc. Common Stock in Q2 2015, an estimated $82.3M increase.
  • Baker Bros. Advisors's biggest Q2 2015 reduction was ANACOR PHARMACEUTICALS INC COM, cutting an estimated $38M.
  • Baker Bros. Advisors fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $2.31B.
  • Baker Bros. Advisors's ten largest holdings make up 75% of its $11.4B portfolio in Q2 2015.
  • Baker Bros. Advisors opened 10 new positions and closed 12 in Q2 2015.
  • Baker Bros. Advisors's portfolio value fell 5.2% quarter-over-quarter to $11.4B.

Based on Baker Bros. Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.